Cargando…
Correction to: Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies
Autores principales: | Vijay, Suresh, Brassier, Anais, Ghosh, Arunabha, Fecarotta, Simona, Abel, Florian, Marulkar, Sachin, Jones, Simon A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923548/ https://www.ncbi.nlm.nih.gov/pubmed/33648526 http://dx.doi.org/10.1186/s13023-021-01753-0 |
Ejemplares similares
-
Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies
por: Vijay, Suresh, et al.
Publicado: (2021) -
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
por: Jones, Simon A., et al.
Publicado: (2017) -
Sebelipase alfa for lysosomal acid lipase deficiency: 5‐year treatment experience from a phase 2 open‐label extension study
por: Malinová, Vĕra, et al.
Publicado: (2020) -
Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization
por: Huffaker, Michelle F., et al.
Publicado: (2019) -
Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa
por: Su, Kim, et al.
Publicado: (2016)